Background: Prostate cancer is the most common neoplasm of American men and the second most common cause of cancer-related deaths. Research suggests that infection and subsequent inflammation may be an important risk factor in the pathogenesis of prostate cancer. In this meta-analysis, we examine the current epidemiological evidence for the association between specific sexually transmitted diseases (STDs) and prostate cancer.
Methods: Using an English language search of Medline and CINAHL (Cumulative Index to Nursing and Allied Health) since 1966, 29 case-control studies were identified. These studies included a total of 6,022 cases of prostate cancer and 7,320 controls. Using Review Manager, combined odds ratios (ORs) were calculated for any STDs, gonorrhea, syphilis, and human papillomavirus (HPV) for prostate cancer.
Results: Significant elevated ORs for prostate cancer were demonstrated for any STDs (1.48, 95% confidence interval [CI] 1.26-1.73), gonorrhea (1.35, 95% CI 1.05-1.83), and human papillomavirus (1.39, 95% CI 1.12-2.06).
Conclusions: This meta-analysis provides evidence of a higher rate of prostate cancer in men with a history of an exposure to gonorrhea, HPV, or any STD. Further research, especially with cohort studies, is required to confirm this potentially modifiable risk factor.
Download full-text PDF |
Source |
---|
Cureus
December 2024
Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, USA.
Disseminated intravascular coagulation (DIC) is a hematological disorder characterized by the abnormal activation of the coagulation system, which leads to widespread clotting and subsequent consumption coagulopathy. DIC is often associated with the progression of prostate cancer and can be a life-threatening condition. In this case report, we present a patient with recurrent DIC in the setting of advanced prostate cancer.
View Article and Find Full Text PDFClin Hematol Int
January 2025
Service d'Hématologie Clinique et Thérapie Cellulaire Hôpital Saint-Antoine.
Individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have a high risk of developing other malignancies (OMs). The development of OMs may be associated with the advanced age of CLL/SLL patients, presence of a tumor-promoting microenvironment, immune alterations inherent to CLL/SLL, or chemotherapy. Importantly, the occurrence of OMs following frontline fludarabine, cyclophosphamide and rituximab (FCR) treatment is associated with a reduction in the overall survival (OS).
View Article and Find Full Text PDFProstate cancer (PC) progresses from benign epithelium through pre-malignant lesions, localized tumors, metastatic dissemination, and castration-resistant stages, with some cases exhibiting phenotype plasticity under therapeutic pressure. However, high-resolution insights into how cell phenotypes evolve across successive stages of PC remain limited. Here, we present the Prostate Cancer Cell Atlas (PCCAT) by integrating ∼710,000 single cells from 197 human samples covering a spectrum of tumor stages.
View Article and Find Full Text PDFUnlabelled: Inadequate response to androgen deprivation therapy (ADT) frequently arises in prostate cancer, driven by cellular mechanisms that remain poorly understood. Here, we integrated single-cell RNA sequencing, single-cell multiomics, and spatial transcriptomics to define the transcriptional, epigenetic, and spatial basis of cell identity and castration response in the mouse prostate. Leveraging these data along with a meta-analysis of human prostates and prostate cancer, we identified cellular orthologs and key determinants of ADT response and resistance.
View Article and Find Full Text PDFFront Immunol
December 2024
Yi-Huan Genitourinary Cancer Group, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Primary small cell neuroendocrine carcinoma of the prostate is extremely rare, highly aggressive, and has a very poor prognosis, with an overall survival typically not exceeding one year. Standard treatment is generally based on the regimen for small cell lung cancer (SCLC), with guidelines recommending etoposide combined with cisplatin (EP regimen) as the first-line treatment. However, their therapeutic effects are limited.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!